Laura Korin, Doctor of the Haematology Service and Unit Of Haematopoietic Transplantation (UTH) of the Alexander Fleming Institute, shared a post on X:
“Why do patients progress on epcoritamab?
EPCORE NHL-1 paired biopsies:
- 61% of progressors lost CD20: MS4A1 mutation (58%) or transcriptional silencing (17%).
- 39% kept CD20, but lost intratumoral CD3+ T cells.
- Antigen escape or T-cell failure: map the mechanism, choose the next treatment.”
Title: Reduced CD20 Expression and Intratumoral CD3+ T Cells Following Epcoritamab Treatment Are Associated With Progressive Disease in a Subset of Diffuse Large B-cell Lymphoma and Follicular Lymphoma
Authors: Monica Wielgos-Bonvallet, Mahesh Bachu, Isil Altintas, Han Si, Kubra Karagoz, Matthew Loya, Prianka Chohan, Scott Milos, Chan Y. Cheah, Eliza Hawkes, Michael Roost Clausen, Christopher Morehouse, Melih Acar, David Soong, Andrew J. Steele
Other articles featuring Laura Korin on OncoDaily.